EXCLUSIVE: Small MedTech Firm NeurAxis Targets $2B Market With Post-Concussion Therapy In Kids

NeurAxis Inc NRXS highlighted A Prospective Study on the Effect of Auricular Percutaneous Electrical Nerve Field Stimulation (PENFS) in Patients with Post-Concussion Syndrome (PCS), a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of IB-Stim in children with post-concussion symptoms.

NeurAxis is a medical technology company commercializing neuromodulation therapies.

Brian Carrico, President and Chief Executive Officer of NeurAxis, said, "We are thrilled to support this research because if the data are positive and the FDA gives clearance, this would be a groundbreaking therapeutic option for post-concussion syndrome."

Also Read: Microsoft Memo Leak Reveals Guidance For Managers: Connect 'Rewards' To Employee 'Impact,' Avoid Salary Freeze Talks

According to the literature, most concussions occur in children, mainly due to sports and unstructured play with or without helmets. While symptoms generally resolve in a few weeks, others persist, including ongoing headaches, nausea, dizziness, and mood and behavioral disorders. 

Medications are primarily used for off-label treatment despite the lack of evidence to support efficacy or safety.

"We support the ongoing pediatric post-concussion clinical research, and it reinforces our commitment to evidence-based research to drive adoption for our PENFS technology, a minimally invasive device alternative, to meet the needs of this $2 billion market," Carrico added.

Currently enrolling up to 100 patients, the clinical trial's primary endpoint is improvements in validated measures, including the Immediate Post-Concussion Assessment, Post-Concussion Symptom Scale, and Balance Error Scoring Symptom compared to placebo. 

The trial is being conducted at Children's Hospital of Orange County, CA.

Price Action: NRXS shares closed at $4.71 on Monday.

Now Read: Tesla Investor Says VinFast, At $200B Market Cap, 'Even Bigger Bubble' Than Nikola Was In 2020